Table 2.
Risk ratio for association between statin exposure and dengue severity.
| Exposure | No. of patients | No. (%) of severe dengue manifestations | Crude RR (95% CI) | P | Adjusted RRa (95% CI) | P | Adjusted RRb (95% CI) | P |
|---|---|---|---|---|---|---|---|---|
| Dengue hemorrhagic fever and shock syndrome: | ||||||||
| Non-users | 66 | 24 (36.4) | 1.00 | 1.00 | 1.00 | |||
| Users | 191 | 56 (29.3) | 0.81 (0.55–1.19) | 0.30 | 0.81 (0.55–2.2) | 0.30 | 0.73 (0.46–1.16) | 0.18 |
| Severe dengue: | ||||||||
| Non-users | 66 | 17 (25.8) | 1.00 | 1.00 | 1.00 | |||
| Users | 191 | 64 (33.5) | 1.30 (0.82–2.05) | 0.26 | 1.28 (0.82–2.01) | 0.28 | 1.52 (0.91–2.53) | 0.11 |
aAdjusted for age, gender.
bAdjusted for age, gender, year of presentation, BMI category, Charlson’s comorbidity index category, hypertension, myocardial infarction, chronic liver disease, concurrent medications usage including anti-platelet drugs, ARB, ACEI, insulin, metformin, sulfonylurea, and lipid panel including LDL-C, HDL-C, triglycerides and total cholesterol as categorical variables.